Drug Delivery and Molecular Sensing Research Program (Project-004)

药物输送和分子传感研究计划： 项目摘要 药物递送和分子传感（DDMS）计划作为PCCR的技术分支， 使成像，分离，生物传感和靶向输送的进步，可以应用于基本的 癌症研究中的发现和转化努力。DDMS由来自11个国家的19名教师组成 普渡大学学术部门。DDMS提供细胞和组织成像、 用于药物测试的药物递送载体和仿生平台，以及将它们结合在一起的新的生物分析方法， 与其他PCCR研究计划协同，促进我们对癌症驱动的理解， 在分子水平上的过程。在上一个CCSG资助期间，从以下国家招募了五名新成员： 应用科学和工程部门，进一步增加DDMS在生物医学领域的多元化优势 成像、生物分析分离和体外测试。DDMS成员共享一个共同的线程， 发明和应用新的癌症检测技术，提高癌症治疗效果 治疗DDMS在这方面非常富有成效，在2010年至2015年期间编写了519份文件。 2014年5月，20%代表与PCCR成员和其他NCI指定癌症的合作互动 中心. DDMS的工作由410万美元的直接费用、同行审查的校外支持来维持。 DDMS围绕三个研究主题构建：（1）癌症生物学和临床成像工具 癌症分析，在晚期脑癌成像和发现新的 与癌症进展相关的基于代谢物的标志物;（2）研究生物分子标记物的技术 过程和生物标志物检测，产生了解码表观遗传途径的新方法 检测活细胞中的RNA转录物，以及从临床血液中检测罕见癌细胞的新平台 （3）分子生物学方法，用于评估癌症治疗对切除的组织样品的影响; 药物传递的共轭物和材料，发现并验证了分子传递系统 在癌症和免疫学的界面上寻找新的靶点，以及针对不同癌症类型的配体。所有 这些研究工作的结果是与PCCR的其他研究项目（如CIS， MC和CSB），并得到了PCCR共享资源的大力支持;此外， 这些进步导致了新的创业公司的创建和知识产权的产生。 DDMS计划领导人一直积极通过组织专题研讨会，招聘 并与 PESO发现组，并围绕癌症相关主题组建团队， 多研究者研究赠款。例子包括体外测试平台，可以解决未满足的需求， 药物递送研究，基于多模式的基于代谢物的癌症标志物的时空分析 成像和三维组织培养模型，用于研究微环境对血管发生的影响。

Drug Delivery and Molecular Sensing Research Program: Project Summary The Drug Delivery and Molecular Sensing (DDMS) Program serves as the technology arm of the PCCR, enabling advances in imaging, separations, biosensing and targeted delivery, that can be applied toward basic discoveries and translational efforts in cancer research. DDMS is comprised of 19 faculty members from 11 Purdue academic departments. DDMS provides collective expertise in cellular and tissue imaging, design of drug delivery vehicles and biomimetic platforms for drug testing, and novel bioanalytical methods that couple synergetically with other PCCR Research Programs and that advance our understanding of cancer-driven processes at the molecular level. During this last CCSG funding period, five new members were recruited from the applied sciences and engineering departments, further increasing DDMS's diverse strengths in biomedical imaging, bioanalytical separations, and in vitro testing. DDMS members share a common thread in the invention and application of new technologies for cancer detection, and for enhancing the effects of cancer treatment. DDMS has been highly productive in this regard, having producing 519 papers between 2010 and May 2014, 20% representing collaborative interactions with PCCR members and other NCI-designated cancer centers. DDMS efforts are sustained by $4.1 million of direct cost, peer-reviewed extramural support. DDMS is structured around three Research Themes: (1) Imaging Tools for Cancer Biology and Clinical Cancer Analysis, with breakthroughs in the imaging of advanced brain cancers and in the discovery of new metabolite-based markers associated with cancer progression; (2) Technologies for Investigating Biomolecular Processes and Biomarker Detection, which has produced novel methods for decoding epigenetic pathways and detecting RNA transcripts in live cells, and new platforms for detecting rare cancer cells from clinical blood samples or for evaluating the impact of cancer therapy on resected tissue samples; and (3) Molecular Conjugates and Materials for Drug Delivery, which has discovered and validated molecular delivery systems for new targets at the interface of cancer and immunology, and targeting ligands for different cancer types. All of these research efforts have resulted in new collaborations with PCCR's other Research Programs (e.g. CIS, MC, and CSB) and have been critically supported by PCCR Shared Resources; moreover, several research advances have resulted in the creation of new startup companies and the generation of intellectual property. DDMS Program Leaders have been active in renewing directions by organizing topical workshops, recruiting and providing mentorship to new members with cancer-focused research projects, in cooperation with the PESO Discovery Group, and assembling teams around cancer-related themes that target the submission of multi-investigator research grants. Examples include in vitro testing platforms that can address unmet needs in drug delivery research, spatiotemporal analysis of metabolite-based cancer markers based on multimodal imaging, and 3-D tissue culture models for investigating microenvironmental effects on vasculogenesis.